ACOR: AI 评分 42/100 — AI 分析 (4月 2026)

Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders. Their key products target multiple sclerosis and Parkinson's disease, with a focus on improving the lives of patients with these conditions.

Key Facts: AI Score: 42/100 Sector: Healthcare

公司概况

概要：

Acorda Therapeutics, Inc. develops and commercializes therapies for neurological disorders, primarily focusing on multiple sclerosis and Parkinson's disease. The company's key products include Ampyra and Inbrija, addressing walking impairment in MS patients and OFF periods in Parkinson's disease, respectively. They operate in the specialty pharmaceutical market, facing competition from both established and emerging players.

ACOR是做什么的？

Acorda Therapeutics, Inc., founded in 1995 and headquartered in Ardsley, New York, is a biopharmaceutical company dedicated to developing and commercializing therapies for neurological disorders. The company's primary focus is on addressing unmet needs in multiple sclerosis (MS) and Parkinson's disease. Acorda's flagship product, Ampyra (dalfampridine), is an oral medication designed to improve walking in patients with MS. Ampyra is also marketed as Fampyra in Europe, Asia, and the Americas. In addition to Ampyra, Acorda markets Inbrija, a treatment for OFF periods in Parkinson's disease, specifically in Europe. The company is also developing ARCUS product for the treatment of acute migraine, rHIgM22, which has completed Phase I clinical trial for the treatment of MS, and Cimaglermin alfa for heart failure patients. Acorda has a collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda's strategy involves a combination of internal research and development, strategic collaborations, and licensing agreements to expand its pipeline and commercial reach. The company's focus on neurological disorders positions it within a growing market driven by an aging population and increasing prevalence of these conditions.

ACOR的投资论点是什么？

Acorda Therapeutics faces significant challenges and opportunities. The company's reliance on Ampyra sales, despite generic competition, presents a risk. However, the continued commercialization of Inbrija in Europe offers a potential growth driver. The success of their pipeline products, such as the ARCUS product for acute migraine, rHIgM22 for MS, and Cimaglermin alfa for heart failure, is crucial for future revenue streams. The company's high gross margin of 60.9% indicates pricing power, but the negative profit margin of -215.0% raises concerns about operational efficiency and expense management. Investors should closely monitor the progress of clinical trials, regulatory approvals, and the impact of generic competition on Ampyra sales.

ACOR在哪个行业运营？

Acorda Therapeutics operates in the specialty pharmaceutical sector, which is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The market for neurological disorder treatments is expanding due to the aging global population and increasing prevalence of conditions like multiple sclerosis and Parkinson's disease. Companies like Acorda face competition from both established pharmaceutical giants and smaller, innovative biotech firms. The industry is also influenced by factors such as patent expirations, generic drug approvals, and pricing pressures from healthcare providers and payers.

Drug Manufacturers - Specialty & Generic

Healthcare

ACOR有哪些增长机遇？

Expansion of Inbrija in European Markets: Acorda has the opportunity to further penetrate the European market with Inbrija, its treatment for OFF periods in Parkinson's disease. The Parkinson's disease market is projected to reach $5.6 billion by 2028, offering a substantial growth opportunity. Successful commercialization and market penetration in key European countries could significantly boost revenue. This expansion relies on effective marketing strategies, favorable reimbursement policies, and positive clinical outcomes.
Advancement of ARCUS Product for Acute Migraine: Acorda is developing ARCUS product for the treatment of acute migraine. The migraine treatment market is estimated to reach $3.5 billion by 2027. Successful development and regulatory approval of ARCUS could provide a significant new revenue stream. This opportunity depends on positive clinical trial results, regulatory approval, and effective market launch.
Development of rHIgM22 for Multiple Sclerosis: Acorda is developing rHIgM22, a treatment for MS, which has completed Phase I clinical trial. The MS market is projected to reach $30 billion by 2028. Positive clinical trial results and regulatory approval could position rHIgM22 as a valuable asset. This opportunity hinges on demonstrating efficacy and safety in subsequent clinical trials.
Commercialization of Cimaglermin alfa for Heart Failure: Acorda is developing Cimaglermin alfa for heart failure patients. The heart failure market is estimated to reach $18 billion by 2029. Successful development and regulatory approval of Cimaglermin alfa could provide a significant new revenue stream. This opportunity depends on positive clinical trial results, regulatory approval, and effective market launch.
Strategic Partnerships and Licensing Agreements: Acorda can pursue strategic partnerships and licensing agreements to expand its pipeline and commercial reach. Collaborating with other pharmaceutical companies or research institutions can provide access to new technologies, drug candidates, and markets. These partnerships can accelerate the development and commercialization of new therapies, reducing risk and increasing potential returns. The success of this strategy depends on identifying and securing mutually beneficial partnerships.

Market capitalization of $0.00B reflects the company's current financial challenges and market perception.
Gross margin of 60.9% indicates strong pricing power for its existing products.
Negative profit margin of -215.0% highlights significant operational inefficiencies and high expenses.
Beta of 1.46 suggests higher volatility compared to the overall market.
The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS).

ACOR提供哪些产品和服务？

Develops and commercializes therapies for neurological disorders.
Markets Ampyra (dalfampridine) to improve walking in patients with multiple sclerosis (MS).
Markets Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.
Develops ARCUS product for the treatment of acute migraine.
Develops rHIgM22 for the treatment of MS.
Develops Cimaglermin alfa for heart failure patients.

ACOR如何赚钱？

Develops and commercializes proprietary pharmaceutical products.
Generates revenue through the sale of prescription drugs.
Partners with other companies for development and commercialization.
Focuses on neurological disorders, specifically MS and Parkinson's disease.

Patients with multiple sclerosis (MS).
Patients with Parkinson's disease.
Healthcare providers who prescribe Acorda's medications.
Pharmacies that dispense Acorda's medications.

Proprietary drug formulations (Ampyra and Inbrija).
Patent protection for key products.
Established relationships with healthcare providers.
Specialized focus on neurological disorders.

什么因素可能推动ACOR股价上涨？

Upcoming: Clinical trial results for ARCUS product for acute migraine.
Upcoming: Regulatory approval decisions for new drug applications.
Ongoing: Commercialization efforts for Inbrija in European markets.
Ongoing: Development of rHIgM22 for multiple sclerosis.
Ongoing: Strategic partnerships and licensing agreements.

ACOR的主要风险是什么？

Ongoing: Generic competition for Ampyra.
Potential: Regulatory setbacks for pipeline products.
Potential: Pricing pressures from healthcare providers.
Potential: Competition from other pharmaceutical companies.
Ongoing: High operating expenses and negative profit margin.

ACOR的核心优势是什么？

Proprietary drug formulations (Ampyra and Inbrija).
Established presence in the MS market.
High gross margin.
Focus on neurological disorders.

ACOR的劣势是什么？

Reliance on Ampyra sales.
Negative profit margin.
Limited product pipeline.
Generic competition for Ampyra.

ACOR有哪些机遇？

Expansion of Inbrija in European markets.
Advancement of ARCUS product for acute migraine.
Development of rHIgM22 for multiple sclerosis.
Strategic partnerships and licensing agreements.

ACOR面临哪些威胁？

Generic competition for Ampyra.
Regulatory challenges.
Pricing pressures from healthcare providers.
Competition from other pharmaceutical companies.

ACOR的竞争对手是谁？

GryNext, Inc. — Focuses on generic pharmaceuticals. — (GRYN)
Hopeco, Inc. — Unknown specific differentiation. — (HPCO)
Laser Diode, Inc. — Unknown specific differentiation. — (LSDI)
Mankin & Sons, Inc. — Unknown specific differentiation. — (MNKKQ)
North Bay Bancorp — Unknown specific differentiation. — (NBGV)

Key Metrics

MoonshotScore: 42/100

Company Profile

CEO: Ron Cohen
Headquarters: Ardsley, US
Employees: 102
Founded: 2006

AI Insight

AI analysis pending for ACOR

常见问题

What does Acorda Therapeutics, Inc. do?

Acorda Therapeutics, Inc. is a biopharmaceutical company that focuses on developing and commercializing therapies for neurological disorders. The company's primary products include Ampyra (dalfampridine), used to improve walking in patients with multiple sclerosis (MS), and Inbrija, a treatment for OFF periods in Parkinson's disease, primarily marketed in Europe. Acorda's business model involves research and development of novel therapies, regulatory approval processes, and commercialization through sales and marketing efforts, with a focus on addressing unmet needs in the neurological disease space.

What do analysts say about ACOR stock?

Analyst coverage of Acorda Therapeutics, Inc. is limited, reflecting the company's small market capitalization and financial challenges. Key valuation metrics, such as price-to-earnings ratio, are often not applicable due to negative earnings. Growth considerations revolve around the success of Inbrija in Europe and the potential of pipeline products. Analyst consensus typically reflects a cautious outlook, given the competitive landscape and financial risks. Investors should conduct their own due diligence and consider multiple factors before making investment decisions.

What are the main risks for ACOR?

Acorda Therapeutics, Inc. faces several significant risks. The primary risk is the generic competition for Ampyra, which has eroded sales and profitability. Regulatory risks associated with the development and approval of new drugs are also a concern. Pricing pressures from healthcare providers and payers can impact revenue. Competition from larger pharmaceutical companies with greater resources poses a threat. Additionally, the company's high operating expenses and negative profit margin create financial instability.

How does Acorda Therapeutics, Inc. manage patent expiration risks?

Acorda Therapeutics, Inc. faces patent expiration risks, particularly concerning Ampyra. To mitigate these risks, the company employs several strategies. These include developing new formulations or delivery methods for existing drugs, pursuing patent extensions where possible, and diversifying the product pipeline through research and development of new therapies. Additionally, Acorda may engage in strategic partnerships or acquisitions to acquire new intellectual property and expand its portfolio of protected products. The success of these strategies is crucial for maintaining revenue streams and long-term growth.

What is Acorda Therapeutics, Inc.'s drug pipeline status?

Acorda Therapeutics, Inc.'s drug pipeline includes several products in various stages of development. The ARCUS product is being developed for the treatment of acute migraine. rHIgM22 has completed Phase I clinical trial for the treatment of MS. Cimaglermin alfa is being developed for heart failure patients. The success of these pipeline products is critical for Acorda's future growth. Investors should monitor clinical trial results, regulatory submissions, and potential commercialization timelines to assess the value of these assets.